Altered association of plasmatic oxytocin with affective stress response in alcohol use disorder - Mayer, Annalina V.; Schwarze, Yana; Stierand, Janine; Voges, Johanna; Schröder, Alexander; Gablentz, Janina von der; Junghanns, Klaus; Voß, Oliver; Krach, Sören; Paulus, Frieder M.; Rademacher, Lena (medRxiv, 2024)
Oxytocin has been proposed to play a role in the development and maintenance of alcohol use disorder (AUD) through its interactions with stress pathways. Empirical evidence that indicates altered associations between endogenous oxytocin and stress reactivity in AUD is currently lacking. In this study, we investigated baseline plasmatic oxytocin concentrations of early-abstinent patients with AUD (N = 40) and matched healthy control participants (N = 37), who completed the Trier Social Stress Test (TSST) as well as a control task on two separate visits. We measured salivary cortisol and pulse rate as indicators of a physiological stress response, and anxiety ratings as an indicator of an affective stress response at multiple time points. Baseline oxytocin levels did not significantly differ between the groups. However, our results suggest an altered association of oxytocin and affective stress responses in participants with AUD: while participants with AUD showed a positive relationship between plasmatic oxytocin levels and stress-induced anxiety increase, the opposite relationship was found in control participants. We did not find evidence for an association of oxytocin with physiological stress responses. Assuming that affective stress responses mediate addiction-related behaviors like craving and relapse, our findings suggest that administering exogenous oxytocin might not be beneficial in treating AUD, at least during the early stages of abstinence.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Else Kroener-Fresenius-Stiftung (to LR, Grant No. 2018_A26). AVM received funding by the Department of Medicine at the University of Luebeck, CS08-2023. YS was funded by the Studienstiftung des Deutschen Volkes.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethics Committee of the University of Luebeck, Germany (AZ 17-077).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData and code of this study are openly available at https://osf.io/gjs5h/